Chemotherapy Induced Anemia - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chemotherapy Induced Anemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Chemotherapy Induced Anemia - Pipeline Review, H2 2016', provides an overview of the Chemotherapy Induced Anemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia
- The report reviews pipeline therapeutics for Chemotherapy Induced Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chemotherapy Induced Anemia therapeutics and enlists all their major and minor projects
- The report assesses Chemotherapy Induced Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chemotherapy Induced Anemia Overview 8
Therapeutics Development 9
Pipeline Products for Chemotherapy Induced Anemia - Overview 9
Chemotherapy Induced Anemia - Therapeutics under Development by Companies 10
Chemotherapy Induced Anemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Chemotherapy Induced Anemia - Products under Development by Companies 15
Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development 16
3SBio Inc. 16
BIOCAD 17
Chong Kun Dang Pharmaceutical Corp. 18
Dr. Reddy's Laboratories Limited 19
Galenica Ltd. 20
Panacea Biotec Limited 21
Pfizer Inc. 22
PharmaEssentia Corporation 23
PhytoHealth Corporation 24
Pieris Pharmaceuticals Inc 25
Sandoz International GmbH 26
SBI Pharmaceuticals Co., Ltd. 27
Therapure Biopharma Inc. 28
Tolero Pharmaceuticals, Inc. 29
Chemotherapy Induced Anemia - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
darbepoetin alfa - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
darbepoetin alfa - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
darbepoetin alfa - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
darbepoetin alfa - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
darbepoetin alfa - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
epoetin alfa - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
epoetin zeta - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ferric carboxymaltose - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
P-1116 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
PHN-013 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
PRS-080 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
SSS-06 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
TBI-304H - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
TP-0184 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
TP-0413 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
TXA-302 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Chemotherapy Induced Anemia - Dormant Projects 63
Chemotherapy Induced Anemia - Discontinued Products 64
Chemotherapy Induced Anemia - Product Development Milestones 65
Featured News & Press Releases 65
Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H 65
Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia 65
Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health 65
Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology 66
Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting 66
Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology 67
Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 67
Aug 09, 2010: Dr Reddy's Launches Darbepoetin Alfa For Treatment Of Anemia In India 68
Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world's first complex biosimilar 68
Jan 07, 2008: Sandoz and Gambro form strategic alliance 69
Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Number of Products under Development for Chemotherapy Induced Anemia, H2 2016 9
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Chemotherapy Induced Anemia - Pipeline by 3SBio Inc., H2 2016 16
Chemotherapy Induced Anemia - Pipeline by BIOCAD, H2 2016 17
Chemotherapy Induced Anemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 18
Chemotherapy Induced Anemia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 19
Chemotherapy Induced Anemia - Pipeline by Galenica Ltd., H2 2016 20
Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Limited, H2 2016 21
Chemotherapy Induced Anemia - Pipeline by Pfizer Inc., H2 2016 22
Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corporation, H2 2016 23
Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corporation, H2 2016 24
Chemotherapy Induced Anemia - Pipeline by Pieris Pharmaceuticals Inc, H2 2016 25
Chemotherapy Induced Anemia - Pipeline by Sandoz International GmbH, H2 2016 26
Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016 27
Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc., H2 2016 28
Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Assessment by Combination Products, H2 2016 31
Number of Products by Stage and Target, H2 2016 33
Number of Products by Stage and Mechanism of Action, H2 2016 35
Number of Products by Stage and Route of Administration, H2 2016 37
Number of Products by Stage and Molecule Type, H2 2016 39
Chemotherapy Induced Anemia - Dormant Projects, H2 2016 63
Chemotherapy Induced Anemia - Discontinued Products, H2 2016 64